APO Research
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Insulin Glargine

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Recombinant Insulin Glargine Industry Growth and Trends Forecast to 2032

23 December 2025104 pages

Choose your research edition.

Industry ResearchRecombinant Insulin Glargine Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Insulin Glargine Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Recombinant Insulin Glargine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Insulin Glargine Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Insulin Glargine Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Recombinant Insulin Glargine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Recombinant Insulin Glargine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Recombinant Insulin Glargine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Insulin Glargine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Recombinant Insulin Glargine include United Laboratories, Tonghua Dongbao, Sanofi, Eli Lilly & Co, Gan & Lee, Wockhardt, Viatris, Swixx Biopharma and Lupin Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Recombinant Insulin Glargine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Recombinant Insulin Glargine market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Recombinant Insulin Glargine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Recombinant Insulin Glargine.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Recombinant Insulin Glargine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Recombinant Insulin Glargine Market by Company

United Laboratories

Tonghua Dongbao

Sanofi

Eli Lilly & Co

Gan & Lee

Wockhardt

Viatris

Swixx Biopharma

Lupin Laboratories

KALBE PHARMA

INFION PHARMA

Cipla

Biocon Biologics

Biocare

Recombinant Insulin Glargine Segment by Type

Vial

Prefilled

Recombinant Insulin Glargine Segment by Application

Type 1 Diabetes

Type 2 Diabetes

Recombinant Insulin Glargine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Insulin Glargine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Insulin Glargine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Insulin Glargine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Recombinant Insulin Glargine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Recombinant Insulin Glargine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Vial Table 2. Major Company of Prefilled Table 3. Global Recombinant Insulin Glargine Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Recombinant Insulin Glargine Sales by Type (2021-2026) & (k units) Table 5. Global Recombinant Insulin Glargine Sales Market Share in Volume by Type (2021-2026) Table 6. Global Recombinant Insulin Glargine Sales by Type (2021-2026) & (US$ Million) Table 7. Global Recombinant Insulin Glargine Sales Market Share in Value by Type (2021-2026) Table 8. Global Recombinant Insulin Glargine Price by Type (2021-2026) & (USD/unit) Table 9. Global Recombinant Insulin Glargine Sales by Type (2027-2032) & (k units) Table 10. Global Recombinant Insulin Glargine Sales Market Share in Volume by Type (2027-2032) Table 11. Global Recombinant Insulin Glargine Sales by Type (2027-2032) & (US$ Million) Table 12. Global Recombinant Insulin Glargine Sales Market Share in Value by Type (2027-2032) Table 13. Global Recombinant Insulin Glargine Price by Type (2027-2032) & (USD/unit) Table 14. North America Recombinant Insulin Glargine Sales by Type (2021-2026) & (k units) Table 15. North America Recombinant Insulin Glargine Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Recombinant Insulin Glargine Sales by Type (2021-2026) & (k units) Table 17. Europe Recombinant Insulin Glargine Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Recombinant Insulin Glargine Sales by Type (2021-2026) & (k units) Table 19. Asia-Pacific Recombinant Insulin Glargine Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Recombinant Insulin Glargine Sales by Type (2021-2026) & (k units) Table 21. Latin America Recombinant Insulin Glargine Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Recombinant Insulin Glargine Sales by Type (2021-2026) & (k units) Table 23. Middle East and Africa Recombinant Insulin Glargine Sales by Type (2021-2026) & (US$ Million) Table 24. Recombinant Insulin Glargine Industry Trends Table 25. Recombinant Insulin Glargine Industry Drivers Table 26. Recombinant Insulin Glargine Industry Opportunities and Challenges Table 27. Recombinant Insulin Glargine Industry Restraints Table 28. Global Recombinant Insulin Glargine Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Recombinant Insulin Glargine Revenue Market Share by Company (2021-2026) Table 30. Global Recombinant Insulin Glargine Sales by Company (2021-2026) & (k units) Table 31. Global Recombinant Insulin Glargine Sales Share by Company (2021-2026) Table 32. Global Recombinant Insulin Glargine Market Price by Company (2021-2026) & (USD/unit) Table 33. Global Recombinant Insulin Glargine Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Recombinant Insulin Glargine Major Company Production Sites and Headquarters Table 35. Global Recombinant Insulin Glargine Company, Product Type & Application Table 36. Global Recombinant Insulin Glargine Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Recombinant Insulin Glargine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Recombinant Insulin Glargine Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Recombinant Insulin Glargine Sales by Region (2021-2026) & (k units) Table 41. Global Recombinant Insulin Glargine Sales Market Share in Volume by Region (2021-2026) Table 42. Global Recombinant Insulin Glargine Sales by Region (2021-2026) & (US$ Million) Table 43. Global Recombinant Insulin Glargine Sales Market Share in Value by Region (2021-2026) Table 44. Global Recombinant Insulin Glargine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 45. Global Recombinant Insulin Glargine Sales by Region (2027-2032) & (k units) Table 46. Global Recombinant Insulin Glargine Sales Market Share in Volume by Region (2027-2032) Table 47. Global Recombinant Insulin Glargine Sales by Region (2027-2032) & (US$ Million) Table 48. Global Recombinant Insulin Glargine Sales Market Share in Value by Region (2027-2032) Table 49. Global Recombinant Insulin Glargine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2027-2032) Table 50. Global Recombinant Insulin Glargine Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Recombinant Insulin Glargine Sales by Application (2021-2026) & (k units) Table 52. Global Recombinant Insulin Glargine Sales Market Share in Volume by Application (2021-2026) Table 53. Global Recombinant Insulin Glargine Sales by Application (2021-2026) & (US$ Million) Table 54. Global Recombinant Insulin Glargine Sales Market Share in Value by Application (2021-2026) Table 55. Global Recombinant Insulin Glargine Price by Application (2021-2026) & (USD/unit) Table 56. Global Recombinant Insulin Glargine Sales by Application (2027-2032) & (k units) Table 57. Global Recombinant Insulin Glargine Sales Market Share in Volume by Application (2027-2032) Table 58. Global Recombinant Insulin Glargine Sales by Application (2027-2032) & (US$ Million) Table 59. Global Recombinant Insulin Glargine Sales Market Share in Value by Application (2027-2032) Table 60. Global Recombinant Insulin Glargine Price by Application (2027-2032) & (USD/unit) Table 61. North America Recombinant Insulin Glargine Sales by Application (2021-2026) & (k units) Table 62. North America Recombinant Insulin Glargine Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Recombinant Insulin Glargine Sales by Application (2021-2026) & (k units) Table 64. Europe Recombinant Insulin Glargine Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Recombinant Insulin Glargine Sales by Application (2021-2026) & (k units) Table 66. Asia-Pacific Recombinant Insulin Glargine Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Recombinant Insulin Glargine Sales by Application (2021-2026) & (k units) Table 68. Latin America Recombinant Insulin Glargine Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Recombinant Insulin Glargine Sales by Application (2021-2026) & (k units) Table 70. Middle East and Africa Recombinant Insulin Glargine Sales by Application (2021-2026) & (US$ Million) Table 71. United Laboratories Company Information Table 72. United Laboratories Business Overview Table 73. United Laboratories Recombinant Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 74. United Laboratories Recombinant Insulin Glargine Product Portfolio Table 75. United Laboratories Recent Development Table 76. Tonghua Dongbao Company Information Table 77. Tonghua Dongbao Business Overview Table 78. Tonghua Dongbao Recombinant Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 79. Tonghua Dongbao Recombinant Insulin Glargine Product Portfolio Table 80. Tonghua Dongbao Recent Development Table 81. Sanofi Company Information Table 82. Sanofi Business Overview Table 83. Sanofi Recombinant Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 84. Sanofi Recombinant Insulin Glargine Product Portfolio Table 85. Sanofi Recent Development Table 86. Eli Lilly & Co Company Information Table 87. Eli Lilly & Co Business Overview Table 88. Eli Lilly & Co Recombinant Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Eli Lilly & Co Recombinant Insulin Glargine Product Portfolio Table 90. Eli Lilly & Co Recent Development Table 91. Gan & Lee Company Information Table 92. Gan & Lee Business Overview Table 93. Gan & Lee Recombinant Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Gan & Lee Recombinant Insulin Glargine Product Portfolio Table 95. Gan & Lee Recent Development Table 96. Wockhardt Company Information Table 97. Wockhardt Business Overview Table 98. Wockhardt Recombinant Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Wockhardt Recombinant Insulin Glargine Product Portfolio Table 100. Wockhardt Recent Development Table 101. Viatris Company Information Table 102. Viatris Business Overview Table 103. Viatris Recombinant Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Viatris Recombinant Insulin Glargine Product Portfolio Table 105. Viatris Recent Development Table 106. Swixx Biopharma Company Information Table 107. Swixx Biopharma Business Overview Table 108. Swixx Biopharma Recombinant Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Swixx Biopharma Recombinant Insulin Glargine Product Portfolio Table 110. Swixx Biopharma Recent Development Table 111. Lupin Laboratories Company Information Table 112. Lupin Laboratories Business Overview Table 113. Lupin Laboratories Recombinant Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Lupin Laboratories Recombinant Insulin Glargine Product Portfolio Table 115. Lupin Laboratories Recent Development Table 116. KALBE PHARMA Company Information Table 117. KALBE PHARMA Business Overview Table 118. KALBE PHARMA Recombinant Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. KALBE PHARMA Recombinant Insulin Glargine Product Portfolio Table 120. KALBE PHARMA Recent Development Table 121. INFION PHARMA Company Information Table 122. INFION PHARMA Business Overview Table 123. INFION PHARMA Recombinant Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. INFION PHARMA Recombinant Insulin Glargine Product Portfolio Table 125. INFION PHARMA Recent Development Table 126. Cipla Company Information Table 127. Cipla Business Overview Table 128. Cipla Recombinant Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Cipla Recombinant Insulin Glargine Product Portfolio Table 130. Cipla Recent Development Table 131. Biocon Biologics Company Information Table 132. Biocon Biologics Business Overview Table 133. Biocon Biologics Recombinant Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. Biocon Biologics Recombinant Insulin Glargine Product Portfolio Table 135. Biocon Biologics Recent Development Table 136. Biocare Company Information Table 137. Biocare Business Overview Table 138. Biocare Recombinant Insulin Glargine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. Biocare Recombinant Insulin Glargine Product Portfolio Table 140. Biocare Recent Development Table 141. North America Recombinant Insulin Glargine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 142. North America Recombinant Insulin Glargine Sales by Country (2021-2026) & (k units) Table 143. North America Recombinant Insulin Glargine Sales Market Share by Country (2021-2026) Table 144. North America Recombinant Insulin Glargine Sales Forecast by Country (2027-2032) & (k units) Table 145. North America Recombinant Insulin Glargine Sales Market Share Forecast by Country (2027-2032) Table 146. North America Recombinant Insulin Glargine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. North America Recombinant Insulin Glargine Market Size by Country (2021-2026) & (US$ Million) Table 148. North America Recombinant Insulin Glargine Market Share by Country (2021-2026) Table 149. North America Recombinant Insulin Glargine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. North America Recombinant Insulin Glargine Market Share Forecast by Country (2027-2032) Table 151. Europe Recombinant Insulin Glargine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 152. Europe Recombinant Insulin Glargine Sales by Country (2021-2026) & (k units) Table 153. Europe Recombinant Insulin Glargine Sales Market Share by Country (2021-2026) Table 154. Europe Recombinant Insulin Glargine Sales Forecast by Country (2027-2032) & (k units) Table 155. Europe Recombinant Insulin Glargine Sales Market Share Forecast by Country (2027-2032) Table 156. Europe Recombinant Insulin Glargine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Europe Recombinant Insulin Glargine Market Size by Country (2021-2026) & (US$ Million) Table 158. Europe Recombinant Insulin Glargine Market Share by Country (2021-2026) Table 159. Europe Recombinant Insulin Glargine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Europe Recombinant Insulin Glargine Market Share Forecast by Country (2027-2032) Table 161. Asia-Pacific Recombinant Insulin Glargine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 162. Asia-Pacific Recombinant Insulin Glargine Sales by Country (2021-2026) & (k units) Table 163. Asia-Pacific Recombinant Insulin Glargine Sales Market Share by Country (2021-2026) Table 164. Asia-Pacific Recombinant Insulin Glargine Sales Forecast by Country (2027-2032) & (k units) Table 165. Asia-Pacific Recombinant Insulin Glargine Sales Market Share Forecast by Country (2027-2032) Table 166. Asia-Pacific Recombinant Insulin Glargine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Asia-Pacific Recombinant Insulin Glargine Market Size by Country (2021-2026) & (US$ Million) Table 168. Asia-Pacific Recombinant Insulin Glargine Market Share by Country (2021-2026) Table 169. Asia-Pacific Recombinant Insulin Glargine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Asia-Pacific Recombinant Insulin Glargine Market Share Forecast by Country (2027-2032) Table 171. Latin America Recombinant Insulin Glargine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 172. Latin America Recombinant Insulin Glargine Sales by Country (2021-2026) & (k units) Table 173. Latin America Recombinant Insulin Glargine Sales Market Share by Country (2021-2026) Table 174. Latin America Recombinant Insulin Glargine Sales Forecast by Country (2027-2032) & (k units) Table 175. Latin America Recombinant Insulin Glargine Sales Market Share Forecast by Country (2027-2032) Table 176. Latin America Recombinant Insulin Glargine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. Latin America Recombinant Insulin Glargine Market Size by Country (2021-2026) & (US$ Million) Table 178. Latin America Recombinant Insulin Glargine Market Share by Country (2021-2026) Table 179. Latin America Recombinant Insulin Glargine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. Latin America Recombinant Insulin Glargine Market Share Forecast by Country (2027-2032) Table 181. Middle East and Africa Recombinant Insulin Glargine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 182. Middle East and Africa Recombinant Insulin Glargine Sales by Country (2021-2026) & (k units) Table 183. Middle East and Africa Recombinant Insulin Glargine Sales Market Share by Country (2021-2026) Table 184. Middle East and Africa Recombinant Insulin Glargine Sales Forecast by Country (2027-2032) & (k units) Table 185. Middle East and Africa Recombinant Insulin Glargine Sales Market Share Forecast by Country (2027-2032) Table 186. Middle East and Africa Recombinant Insulin Glargine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 187. Middle East and Africa Recombinant Insulin Glargine Market Size by Country (2021-2026) & (US$ Million) Table 188. Middle East and Africa Recombinant Insulin Glargine Market Share by Country (2021-2026) Table 189. Middle East and Africa Recombinant Insulin Glargine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 190. Middle East and Africa Recombinant Insulin Glargine Market Share Forecast by Country (2027-2032) Table 191. Key Raw Materials Table 192. Raw Materials Key Suppliers Table 193. Recombinant Insulin Glargine Distributors List Table 194. Recombinant Insulin Glargine Customers List Table 195. Research Programs/Design for This Report Table 196. Authors List of This Report Table 197. Secondary Sources Table 198. Primary Sources List of Figures Figure 1. Recombinant Insulin Glargine Image Figure 2. Global Recombinant Insulin Glargine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Insulin Glargine Market Size (2021-2032) & (US$ Million) Figure 4. Global Recombinant Insulin Glargine Sales (2021-2032) & (k units) Figure 5. Vial Image Figure 6. Global Vial Sales YoY Growth (2021-2032) & (k units) Figure 7. Prefilled Image Figure 8. Global Prefilled Sales YoY Growth (2021-2032) & (k units) Figure 9. Global Recombinant Insulin Glargine Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Recombinant Insulin Glargine Market Share by Type 2025 VS 2032 Figure 11. North America Recombinant Insulin Glargine Sales Market Share in Volume by Type in 2025 Figure 12. North America Recombinant Insulin Glargine Sales Market Share in Value by Type in 2025 Figure 13. Europe Recombinant Insulin Glargine Sales Market Share in Volume by Type in 2025 Figure 14. Europe Recombinant Insulin Glargine Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Recombinant Insulin Glargine Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Recombinant Insulin Glargine Sales Market Share in Value by Type in 2025 Figure 17. Latin America Recombinant Insulin Glargine Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Recombinant Insulin Glargine Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Recombinant Insulin Glargine Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Recombinant Insulin Glargine Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Recombinant Insulin Glargine Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Type 1 Diabetes Image Figure 24. Global Type 1 Diabetes Sales YoY Growth (2021-2032) & (k units) Figure 25. Type 2 Diabetes Image Figure 26. Global Type 2 Diabetes Sales YoY Growth (2021-2032) & (k units) Figure 27. Global Recombinant Insulin Glargine Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global Recombinant Insulin Glargine Market Share by Application 2025 VS 2032 Figure 29. North America Recombinant Insulin Glargine Sales Market Share in Volume by Application in 2025 Figure 30. North America Recombinant Insulin Glargine Sales Market Share in Value by Application in 2025 Figure 31. Europe Recombinant Insulin Glargine Sales Market Share in Volume by Application in 2025 Figure 32. Europe Recombinant Insulin Glargine Sales Market Share in Value by Application in 2025 Figure 33. Asia-Pacific Recombinant Insulin Glargine Sales Market Share in Volume by Application in 2025 Figure 34. Asia-Pacific Recombinant Insulin Glargine Sales Market Share in Value by Application in 2025 Figure 35. Latin America Recombinant Insulin Glargine Sales Market Share in Volume by Application in 2025 Figure 36. Latin America Recombinant Insulin Glargine Sales Market Share in Value by Application in 2025 Figure 37. Middle East and Africa Recombinant Insulin Glargine Sales Market Share in Volume by Application in 2025 Figure 38. Middle East and Africa Recombinant Insulin Glargine Sales Market Share in Value by Application in 2025 Figure 39. North America Recombinant Insulin Glargine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 40. North America Recombinant Insulin Glargine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 41. North America Recombinant Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. North America Recombinant Insulin Glargine Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Recombinant Insulin Glargine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 44. Europe Recombinant Insulin Glargine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Recombinant Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Recombinant Insulin Glargine Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Asia-Pacific Recombinant Insulin Glargine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 48. Asia-Pacific Recombinant Insulin Glargine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Recombinant Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Asia-Pacific Recombinant Insulin Glargine Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Recombinant Insulin Glargine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. Latin America Recombinant Insulin Glargine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Recombinant Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Recombinant Insulin Glargine Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Middle East and Africa Recombinant Insulin Glargine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Middle East and Africa Recombinant Insulin Glargine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Recombinant Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Middle East and Africa Recombinant Insulin Glargine Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Recombinant Insulin Glargine Value Chain Figure 60. Key Raw Materials Price Figure 61. Manufacturing Cost Structure Figure 62. Recombinant Insulin Glargine Production Mode & Process Figure 63. Direct Comparison with Distribution Share Figure 64. Distributors Profiles Figure 65. Years Considered Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Vial
  • Prefilled
Applications
  • Type 1 Diabetes
  • Type 2 Diabetes
Companies covered
  • United Laboratories
  • Tonghua Dongbao
  • Sanofi
  • Eli Lilly & Co
  • Gan & Lee
  • Wockhardt
  • Viatris
  • Swixx Biopharma
  • Lupin Laboratories
  • KALBE PHARMA
  • INFION PHARMA
  • Cipla
  • Biocon Biologics
  • Biocare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Recombinant Insulin Glargine Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Recombinant Insulin Glargine Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Recombinant Insulin Glargine Market by Type
  6. 1.3.1 Vial
  7. 1.3.2 Prefilled
  8. 1.4 Global Recombinant Insulin Glargine Market Size by Type
  9. 1.4.1 Global Recombinant Insulin Glargine Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Recombinant Insulin Glargine Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Recombinant Insulin Glargine Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Recombinant Insulin Glargine Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Recombinant Insulin Glargine Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Recombinant Insulin Glargine Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Recombinant Insulin Glargine Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Recombinant Insulin Glargine Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Recombinant Insulin Glargine Industry Trends
  2. 2.2 Recombinant Insulin Glargine Industry Drivers
  3. 2.3 Recombinant Insulin Glargine Industry Opportunities and Challenges
  4. 2.4 Recombinant Insulin Glargine Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Recombinant Insulin Glargine Revenue (2021-2026)
  2. 3.2 Global Top Players by Recombinant Insulin Glargine Sales (2021-2026)
  3. 3.3 Global Top Players by Recombinant Insulin Glargine Price (2021-2026)
  4. 3.4 Global Recombinant Insulin Glargine Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Recombinant Insulin Glargine Major Company Production Sites & Headquarters
  6. 3.6 Global Recombinant Insulin Glargine Company, Product Type & Application
  7. 3.7 Global Recombinant Insulin Glargine Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Recombinant Insulin Glargine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Recombinant Insulin Glargine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Recombinant Insulin Glargine Tier 1, Tier 2, and Tier 3
4 Recombinant Insulin Glargine Regional Status and Outlook
  1. 4.1 Global Recombinant Insulin Glargine Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Recombinant Insulin Glargine Historic Market Size by Region
  3. 4.2.1 Global Recombinant Insulin Glargine Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Recombinant Insulin Glargine Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Recombinant Insulin Glargine Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Recombinant Insulin Glargine Forecasted Market Size by Region
  7. 4.3.1 Global Recombinant Insulin Glargine Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Recombinant Insulin Glargine Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Recombinant Insulin Glargine Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Recombinant Insulin Glargine by Application
  1. 5.1 Recombinant Insulin Glargine Market by Application
  2. 5.1.1 Type 1 Diabetes
  3. 5.1.2 Type 2 Diabetes
  4. 5.2 Global Recombinant Insulin Glargine Market Size by Application
  5. 5.2.1 Global Recombinant Insulin Glargine Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Recombinant Insulin Glargine Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Recombinant Insulin Glargine Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Recombinant Insulin Glargine Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Recombinant Insulin Glargine Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Recombinant Insulin Glargine Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Recombinant Insulin Glargine Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Recombinant Insulin Glargine Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 United Laboratories
  2. 6.1.1 United Laboratories Company Information
  3. 6.1.2 United Laboratories Business Overview
  4. 6.1.3 United Laboratories Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 United Laboratories Recombinant Insulin Glargine Product Portfolio
  6. 6.1.5 United Laboratories Recent Developments
  7. 6.2 Tonghua Dongbao
  8. 6.2.1 Tonghua Dongbao Company Information
  9. 6.2.2 Tonghua Dongbao Business Overview
  10. 6.2.3 Tonghua Dongbao Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Tonghua Dongbao Recombinant Insulin Glargine Product Portfolio
  12. 6.2.5 Tonghua Dongbao Recent Developments
  13. 6.3 Sanofi
  14. 6.3.1 Sanofi Company Information
  15. 6.3.2 Sanofi Business Overview
  16. 6.3.3 Sanofi Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Sanofi Recombinant Insulin Glargine Product Portfolio
  18. 6.3.5 Sanofi Recent Developments
  19. 6.4 Eli Lilly & Co
  20. 6.4.1 Eli Lilly & Co Company Information
  21. 6.4.2 Eli Lilly & Co Business Overview
  22. 6.4.3 Eli Lilly & Co Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Eli Lilly & Co Recombinant Insulin Glargine Product Portfolio
  24. 6.4.5 Eli Lilly & Co Recent Developments
  25. 6.5 Gan & Lee
  26. 6.5.1 Gan & Lee Company Information
  27. 6.5.2 Gan & Lee Business Overview
  28. 6.5.3 Gan & Lee Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Gan & Lee Recombinant Insulin Glargine Product Portfolio
  30. 6.5.5 Gan & Lee Recent Developments
  31. 6.6 Wockhardt
  32. 6.6.1 Wockhardt Company Information
  33. 6.6.2 Wockhardt Business Overview
  34. 6.6.3 Wockhardt Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Wockhardt Recombinant Insulin Glargine Product Portfolio
  36. 6.6.5 Wockhardt Recent Developments
  37. 6.7 Viatris
  38. 6.7.1 Viatris Company Information
  39. 6.7.2 Viatris Business Overview
  40. 6.7.3 Viatris Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Viatris Recombinant Insulin Glargine Product Portfolio
  42. 6.7.5 Viatris Recent Developments
  43. 6.8 Swixx Biopharma
  44. 6.8.1 Swixx Biopharma Company Information
  45. 6.8.2 Swixx Biopharma Business Overview
  46. 6.8.3 Swixx Biopharma Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Swixx Biopharma Recombinant Insulin Glargine Product Portfolio
  48. 6.8.5 Swixx Biopharma Recent Developments
  49. 6.9 Lupin Laboratories
  50. 6.9.1 Lupin Laboratories Company Information
  51. 6.9.2 Lupin Laboratories Business Overview
  52. 6.9.3 Lupin Laboratories Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Lupin Laboratories Recombinant Insulin Glargine Product Portfolio
  54. 6.9.5 Lupin Laboratories Recent Developments
  55. 6.10 KALBE PHARMA
  56. 6.10.1 KALBE PHARMA Company Information
  57. 6.10.2 KALBE PHARMA Business Overview
  58. 6.10.3 KALBE PHARMA Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 KALBE PHARMA Recombinant Insulin Glargine Product Portfolio
  60. 6.10.5 KALBE PHARMA Recent Developments
  61. 6.11 INFION PHARMA
  62. 6.11.1 INFION PHARMA Company Information
  63. 6.11.2 INFION PHARMA Business Overview
  64. 6.11.3 INFION PHARMA Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 INFION PHARMA Recombinant Insulin Glargine Product Portfolio
  66. 6.11.5 INFION PHARMA Recent Developments
  67. 6.12 Cipla
  68. 6.12.1 Cipla Company Information
  69. 6.12.2 Cipla Business Overview
  70. 6.12.3 Cipla Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Cipla Recombinant Insulin Glargine Product Portfolio
  72. 6.12.5 Cipla Recent Developments
  73. 6.13 Biocon Biologics
  74. 6.13.1 Biocon Biologics Company Information
  75. 6.13.2 Biocon Biologics Business Overview
  76. 6.13.3 Biocon Biologics Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Biocon Biologics Recombinant Insulin Glargine Product Portfolio
  78. 6.13.5 Biocon Biologics Recent Developments
  79. 6.14 Biocare
  80. 6.14.1 Biocare Company Information
  81. 6.14.2 Biocare Business Overview
  82. 6.14.3 Biocare Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Biocare Recombinant Insulin Glargine Product Portfolio
  84. 6.14.5 Biocare Recent Developments
7 North America by Country
  1. 7.1 North America Recombinant Insulin Glargine Sales by Country
  2. 7.1.1 North America Recombinant Insulin Glargine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Recombinant Insulin Glargine Sales by Country (2021-2026)
  4. 7.1.3 North America Recombinant Insulin Glargine Sales Forecast by Country (2027-2032)
  5. 7.2 North America Recombinant Insulin Glargine Market Size by Country
  6. 7.2.1 North America Recombinant Insulin Glargine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Recombinant Insulin Glargine Market Size by Country (2021-2026)
  8. 7.2.3 North America Recombinant Insulin Glargine Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Recombinant Insulin Glargine Sales by Country
  2. 8.1.1 Europe Recombinant Insulin Glargine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Recombinant Insulin Glargine Sales by Country (2021-2026)
  4. 8.1.3 Europe Recombinant Insulin Glargine Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Recombinant Insulin Glargine Market Size by Country
  6. 8.2.1 Europe Recombinant Insulin Glargine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Recombinant Insulin Glargine Market Size by Country (2021-2026)
  8. 8.2.3 Europe Recombinant Insulin Glargine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Recombinant Insulin Glargine Sales by Country
  2. 9.1.1 Asia-Pacific Recombinant Insulin Glargine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Recombinant Insulin Glargine Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Recombinant Insulin Glargine Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Recombinant Insulin Glargine Market Size by Country
  6. 9.2.1 Asia-Pacific Recombinant Insulin Glargine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Recombinant Insulin Glargine Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Recombinant Insulin Glargine Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Recombinant Insulin Glargine Sales by Country
  2. 10.1.1 South America Recombinant Insulin Glargine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Recombinant Insulin Glargine Sales by Country (2021-2026)
  4. 10.1.3 South America Recombinant Insulin Glargine Sales Forecast by Country (2027-2032)
  5. 10.2 South America Recombinant Insulin Glargine Market Size by Country
  6. 10.2.1 South America Recombinant Insulin Glargine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Recombinant Insulin Glargine Market Size by Country (2021-2026)
  8. 10.2.3 South America Recombinant Insulin Glargine Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Recombinant Insulin Glargine Sales by Country
  2. 11.1.1 Middle East and Africa Recombinant Insulin Glargine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Recombinant Insulin Glargine Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Recombinant Insulin Glargine Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Recombinant Insulin Glargine Market Size by Country
  6. 11.2.1 Middle East and Africa Recombinant Insulin Glargine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Recombinant Insulin Glargine Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Recombinant Insulin Glargine Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Recombinant Insulin Glargine Value Chain Analysis
  2. 12.1.1 Recombinant Insulin Glargine Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Recombinant Insulin Glargine Production Mode & Process
  7. 12.2 Recombinant Insulin Glargine Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Recombinant Insulin Glargine Distributors
  10. 12.2.3 Recombinant Insulin Glargine Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst